A recent study reports that the cross-sectional location of gastric cancer is associated with long-term survival outcomes of patients as tumor invasion deepens, published in Annals of Surgical Oncology (online October 4, 2017; doi:10.1245/s10434-017-6101-2).
A recent study compared the effects of adjuvant chemotherapy and observation after preoperative chemoradiation and resection in gastroesophageal cancer, published in JAMA Oncology (online September 21, 2017; doi:10.1001/jamaoncol.2017.2805).
High expression of a specific protein is associated with an improved 5-year survival rate of almost 28% in gastric cancer, according to new research published in PLOS One (online August 30, 2017; doi:10.1371/journal.pone.0183868).
Recent research compared the efficacy of chemotherapy vs best supportive care, combination vs single-agent chemotherapy, and multiple different chemotherapy combinations in advanced gastric cancer (doi:10.1002/14651858.CD004064.pub4).
Recommended primary treatment for non-muscle invasive micropapillary urothelial carcinoma (MPBC) is often foregone in community cancer centers and academic centers, according to a study presented at the American Urological Association (AUA) Annual Meeting (May 12-16, 2017; Boston, MA).
Adding cetuximab to chemoradiation for squamous cell carcinoma of the anal canal is associated with lower incidence of locoregional failure but high toxicity, according to the results of a study published in the Journal of Clinical Oncology (March 2017;35:718-726).
Imatinib mesylate front-line treatment of advanced or metastatic gastrointestinal stromal tumors (GISTs) leads to significant long-term survival in patients with a specific genetic mutation, according to study published in JAMA Oncology (published online February 9, 2017; doi:10.1001/jamaoncol.2016.6728).